AKTS (Aktis Oncology) Short Interest


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.15
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AKTS vs OLMA, EYPT, ZBIO: Short Interest Comparison

For the Biotechnology subindustry, Aktis Oncology's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aktis Oncology Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's Short Interest distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's Short Interest falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.15
Price